Yuchao Chen
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$4.5MFederal grants as PI12 awards
5Patents grantedLatest Sep 16, 2025
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $4.5M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 13, 2025 | NIH | SBIR Phase II Multi-omics profiling of individual exosomes for origin-tracing, biomarker discovery, and biological function characterization | $123K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Jun 9, 2025 | NIH | SBIR Phase II Multi-omics profiling of individual exosomes for origin-tracing, biomarker discovery, and biological function characterization | $738K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Jul 25, 2024 | NIH | SBIR Phase II Multi-omics profiling of individual exosomes for origin-tracing, biomarker discovery, and biological function characterization | $801K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Jun 13, 2023 | NIH | SBIR Phase II A Label-free Extracellular-vesicle Automated Purification System (LEAP System) | $749K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Sep 21, 2022 | NIH | SBIR Phase I EXODOTS for diagnostic evaluation and monitoring of Alzheimer's disease | $292K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Aug 29, 2022 | NIH | STTR Phase I EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease | $110K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Aug 12, 2022 | NIH | SBIR Phase I Link phenotypic characteristics with gene expression profile of single cells at high throughput for drug discovery and cell therapy development | $247K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Jun 16, 2022 | NIH | SBIR Phase II A Label-free Extracellular-vesicle Automated Purification System (LEAP System) | $750K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Mar 28, 2022 | NIH | SBIR Phase I Multi-omics profiling of individual exosomes for their origin-tracing, biomarker discovery, and biological function characterization | $7K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Feb 10, 2022 | NIH | SBIR Phase I Multi-omics profiling of individual exosomes for their origin-tracing, biomarker discovery, and biological function characterization | $250K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Sep 21, 2021 | NIH | STTR Phase I EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease | $251K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
| Aug 18, 2021 | NIH | SBIR Phase I A Label-free Extracellular-vesicle Automated Purification System (LEAP System) | $198K | WELLSIM BIOMEDICAL TECHNOLOGIES, INC. |
6 patents as inventor
- US 11414696WELLSIM BIOMEDICAL TECHNOLOGIES, INC.Aug 16, 2022
- US 11826707WELLSIM BIOMEDICAL TECHNOLOGIES, INC.Nov 28, 2023
- US 11946932WELLSIM BIOMEDICAL TECHNOLOGIES, INC.Apr 2, 2024
- US 12055552WELLSIM BIOMEDICAL TECHNOLOGIES, INC.Aug 6, 2024
- US 12416039WELLSIM BIOMEDICAL TECHNOLOGIES, INC.Sep 16, 2025
- US WELLSIM BIOMEDICAL TECHNOLOGIES, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#320
Awards as PI#86
Patents#25
Companies
- WELLSIM BIOMEDICAL TECHNOLOGIES, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.